CLEOCIN T (clindamycin phosphate) by Pfizer is mechanism of action the mechanism of action of clindamycin in treating acne vulgaris is unknown. Approved for acne vulgaris, bacterial vaginosis. First approved in 1989.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
CLEOCIN T (clindamycin phosphate) is a topical antibiotic lotion approved in 1989 for treating acne vulgaris and bacterial vaginosis. The mechanism of action in acne is unknown, though clindamycin is a lincosamide antibiotic with broad-spectrum bacterial activity. It represents a legacy dermatology product in the topical anti-acne market.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a shrinking team and transition from growth to maintenance mode.
Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris
W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers
Worked on CLEOCIN T at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLEOCIN T is a legacy Pfizer dermatology product with minimal new job creation (0 linked positions); roles focus on defending market share against newer competitors and managing transition to generic competition. Career development on this product emphasizes operational excellence, key opinion leader engagement, and combination therapy positioning rather than innovation or market expansion.